AP
TARA icon

Aspect Partners’s Protara Therapeutics TARA Stock Holding History

Aspect Partners’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$879 Buy
230
+124
+117% +$590 ﹤0.01% 589
2026
Q1 		$552 Buy
+106
New +$627 ﹤0.01% 651

Other funds holding TARA

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
SIC
SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Aspect Partners's TARA Position: Q2 2026 in Review

Aspect Partners increased its Protara Therapeutics (TARA) stake by 117% in Q2 2026, buying an estimated $590 and bringing the position to 230 shares worth $879. The position accounts for ﹤0.01% of the portfolio, ranked #589.

Aspect Partners first reported a position in TARA in Q1 2026 and has held it in 2 quarters since. 11 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Aspect Partners held 230 shares of Protara Therapeutics worth $879 as of Q2 2026.
  • Aspect Partners bought 124 Protara Therapeutics shares in Q2 2026, an estimated $590.
  • Protara Therapeutics made up ﹤0.01% of Aspect Partners's portfolio in Q2 2026, its #589 holding.
  • Aspect Partners first reported a position in Protara Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 11 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Aspect Partners's 13F filing for Q2 2026, filed 16 Jul 2026.